IMVT
Immunovant Inc

2,203
Mkt Cap
$5.22B
Volume
245,701.00
52W High
$27.92
52W Low
$12.72
PE Ratio
-9.56
IMVT Fundamentals
Price
$25.85
Prev Close
$25.64
Open
$25.59
50D MA
$25.70
Beta
1.02
Avg. Volume
1.52M
EPS (Annual)
-$2.73
P/B
5.29
Rev/Employee
$0.00
$1,876.52
Loading...
Loading...
News
all
press releases
FY2026 EPS Forecast for Immunovant Increased by Analyst
Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Immunovant in a report issued on Tuesday, February 10th. HC Wainwright...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Zacks·4d ago
News Placeholder
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Earnings Beat
Immunovant (NASDAQ:IMVT) Sets New 12-Month High Following Earnings Beat...
MarketBeat·4d ago
News Placeholder
Immunovant (NASDAQ:IMVT) Announces Earnings Results, Beats Estimates By $0.10 EPS
Immunovant (NASDAQ:IMVT - Get Free Report) issued its earnings results on Friday. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by...
MarketBeat·7d ago
News Placeholder
Immunovant (IMVT) Q2 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·7d ago
News Placeholder
Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings
Immunovant (NASDAQ:IMVT) Shares Gap Up on Strong Earnings...
MarketBeat·7d ago
News Placeholder
Immunovant Q3 Earnings Call Highlights
Roivant reported third quarter fiscal 2025 financial results and highlighted new Phase 2 data for brepocitinib (BREPA) in cutaneous sarcoidosis, alongside a series of clinical and corporate updates...
MarketBeat·7d ago
News Placeholder
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·11d ago
News Placeholder
Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday
Immunovant (NASDAQ:IMVT) will be releasing its Q3 2026 earnings before the market opens on Friday, February 6. (View Earnings Report at...
MarketBeat·14d ago
News Placeholder
Investors Purchase High Volume of Call Options on Immunovant (NASDAQ:IMVT)
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders bought 2,610 call options on the company. This represents an increase of...
MarketBeat·18d ago
<
1
2
...
>

Latest IMVT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.